RCT in 42 patients with chronic central serous chorioretinopathy without CNVM (39 analysed): >20% macular thickness reduction at 1 month in 77.27% with intravitreal brolucizumab vs 37.5% of controls (p=.01); visual acuity change was not significant.
RCTn = 42
Ramamurthy et al. A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II